Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 5, 2004, Pages 639-648

  Mol, Clifford D ^a   Fabbro, Doriano ^b   Hosfield, David J ^a  

^a Takeda San Diego Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer drugs; Kinase; Leukemia; Receptors; Signal transduction; X ray crystal structures

Indexed keywords

AAL 933; AAL 993; ABELSON KINASE; DORAMAPIMOD; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; UREA DERIVATIVE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CROHN DISEASE; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; HUMAN; NONHUMAN; PROTEIN DOMAIN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; X RAY CRYSTALLOGRAPHY;

CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 4944261336     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Asaoka Y, Nakamura S, Yoshida K, Nishizuka Y: Protein kinase C, calcium and phospholipid degradation. Trends Biochem Sci (1992) 17(10):414-417.
2. 2+ dependent protein kinase. Biochem Biophys Res Commun (1986) 135(2):397-402.
3. Fabbro D, Buchdunger E, Wood J, Mestan J, Hoffman F, Ferrari S, Mett H, O'Reilly T, Meyer T: Inhibitors of protein kinases: CGP 41251 a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther (1999) 82(2-3):293-301.
4. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T: PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des (2000) 15(1):17-28.
5. Zimmermann J, Caravatti G, Mett H, Meyer T, Muller M, Lydon NB, Fabbro D: Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm (Weinheim) (1996) 329(7):371-376.
6. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lyndon NB, Traxler P: Phenylamino pyrimidine (PAP) derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg Med Chem Lett (1996) 6(11):1221-1226.
7. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB: Potent and selective inhibitors of the Abl-kinase: Phenylamino-pyrimidine (PAP) derivatives. Bioorg Med Chem Lett (1997) 7(2):187-192.
8. Zimmermann J, Furet P, Buchdunger E: STI571 - A new treatment modality for CML? In: Anticancer Agents: Frontiers in Cancer Therapy. Ojima G IV, Altmann K (Eds), American Chemical Society, Washington, DC, USA (2001):245-259.
9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2(5):561-566.
10. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H et al: Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmacol Ther (2002) 93(2-3):79-98.
11. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW: Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem (2004) 4(3):285-299.
12. Wolff NC, Ilaria RL Jr: Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood (2001) 98(9):2808-2816.
13. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood (2002) 99(10):3530-3539.
14. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood (2002) 99(6):1928-1937.
15. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 344(14):1038-1042.
16. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D et al: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood (2002) 99(10):3547-3553.
17. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 346(9):645-652.
18. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 348(11):994-1004.
19. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH: Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet (2002) 359(9317):1577-1578.
20. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG et al: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood (2003) 102(9):3093-3096.
21. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 299(5607):708-710.
22. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med (2002) 347(7):481-487.
23. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood (2002) 100(3):1088-1091.
24. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR: Differential sensitivity to imatinib of two patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer (2002) 100(6):623-626.
25. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol (2002) 20(17):3586-3591.
26. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 21(23):4342-4349.
27. Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of Kit tyrosine kinase activity: A novel molecular approach to the treatment of Kit-positive malignancies. J Clin Oncol (2002) 20(6):1692-1703.
28. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 344(14):1052-1056.
29. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet (2001) 358(9291):1421-1423.
30. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol (2002) 3(11):655-664.
31. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res (2002) 62(19):5476-5484.
32. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res (2001) 61(7):2929-2934.
33. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, McSheehy P, Wartmann M, Ostman A: STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res (2003) 9(10 Pt 1):3779-3787.
34. Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of Bcr-Abl. Cell (2003) 112(6):831-843.
35. Nagar B, Bommann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 62(15):4236-4243. The structural results in this paper confirmed that STI-571 targets an inactive DFG-out conformation of Abl. A structure of Abl in complex with PD-173955 (Pfizer Inc), which targets an active conformation, is also presented.
36. Schindler T, Bommann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science (2000) 289(5486):1938-1942. The first description of the structural interactions of a PAP inhibitor related to STI-571, bound to the kinase domain of Abl.
37. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J: Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 112(6):859-871. Provides structural results that describe how the N-terminal SH2 and SH3 domains of Abl, an N-terminal myristoyl modification, and STI-571 maintain the kinase in an autoinhibited conformation.
38. Hubbard SR, Wei L, Ellis L, Hendrickson WA: Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature (1994) 372(6508):746-754.
39. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-Kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J (1987) 6(11):3341-3351.
40. Claesson-Welsh L, Hammacher A, Westermark B, Heldin CH, Nister M: Identification and structural analysis of the A type receptor for platelet-derived growth factor. Similarities with the B type receptor. J Biol Chem (1989) 264(3):1742-1747.
41. Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U et al: Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature (1986) 323(6085):226-232.
42. Bohmer FD, Karagyozov L, Uecker A, Serve H, Botzki A, Mahboobi S, Dove S: A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem (2003) 278(7):5148-5155.
43. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC, Nowakowski J, Kassel DB, Cronin CN, McRee DE: Structure of a c-Kit product complex reveals the basis for kinase transactivation. J Biol Chem (2003) 278(34):31461-31464. Provides the first structure of a type III RPTK, which reveals the active protein conformation that is resistant to STI-571 inhibition and is thus a relevant target for inhibitors that target the escape mutants that activate the enzyme.
44. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem (2004) 279 (30):31655-31663. Provides the second structure of a type III RPTK in an autoinhibited conformation, and includes a comparison with the active, phosphorylated structure as well as the first co-crystal structure of STI-571 bound to a kinase other than Abl.
45. Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K: The structural basis for autoinhibition of Flt-3 by the juxtamembrane domain. Mol Cell (2004) 13(2):169-178. Describes the first autoinhibited structure of an intact type III RPTK and provides a thorough and detailed description of the interactions of the JM region with kinase domains.
46. Hubbard SR: Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol (2004) 5(6):464-471. A thorough and timely review of the structural and biochemical data for how the JM region negatively regulates receptor protein kinase activity.
47. Hubbard SR: Theme and variations: Juxtamembrane regulation of receptor protein kinases. Mol Cell (2001) 8(3):481-482.
48. Huse M, Kuriyan J: The conformational plasticity of protein kinases. Cell (2002) 109(3):275-282. An excellent review that describes the structural changes that occur as a kinase switches from the active on-state to an inactive off-state.
49. Dibb NJ, Mol CD: Switching on kinases - Oncogenic activation of b-Raf and the PDGF receptor family. Nat Cancer Rev (2004) 4(9):718-727.
50. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C et al: Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem (2002) 45(14):2994-3008.
51. Regan J, Capolino A, Cirillo PF, Gilmore T, Graham AG, Hickey E, Kroe RR, Madwed J, Moriak M, Nelson R, Pargellis CA et al: Structure-activity relationships of the p38α MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl- 2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796). J Med Chem (2003) 46(22):4676-4686.
52. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9(4):268-272. Reports the first observation of a DFG-out conformation in a Ser/Thr kinase, indicating that this conformational state may be a more common mechanism for inactivating kinase activity. Inhibitor binding utilizes many similar interactions to those seen in kinase complexes with STI-571.
53. Smith RA, Barbosa J, Blum CL, Bobko MA, Caringal YV, Dally R, Johnson JS, Katz ME, Kennure N, Kingery-Wood J, Lee W et al: Discovery of heterocyclic ureas as a new class of Raf kinase inhibitors: Identification of a second generation lead by a combinatorial chemistry approach. Bioorg Med Chem Lett (2001) 11(20):2775-2778.
54. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R et al: Mechanism of activation of the Raf-ERK signaling pathway by oncogenic mutations of b-Raf. Cell (2004) 116(6):855-867. Describes the first crystal structure of b-Raf kinase, mutations of which are implicated in a majority of malignant melanomas. The structure shows how the inhibitor BAY-43-9006 targets an inactive kinase conformation and provides a structural basis for understanding activating mutants.
55. Manley PW, Furet P, Bold G, Bruggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A et al: Anthranilic acid amides: A novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem (2002) 45(26):5687-5693.
56. Manley PW, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W et al: Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta (2004) 1697(1-2):17-27. Describes the characterization of a new series of anthralic acid amide inhibitors of VEGFR-2. Combined co-crystal structure analysis of one of these inhibitors (AAL-993) bound to VEGFR-2 reveals that the inhibitor targets an inactive conformation of the enzyme.